trending Market Intelligence /marketintelligence/en/news-insights/trending/0v7MLuia8UBEEEQWsLFsWA2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us
In This List

Eton Pharmaceuticals' injectable hypotension drug gets US FDA nod

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


Eton Pharmaceuticals' injectable hypotension drug gets US FDA nod

Eton Pharmaceuticals Inc. received the U.S. Food and Drug Administration's approval for Biorphen to treat low blood pressure caused by the dilation of blood vessels due to anesthesia intake.

Biorphen, which is an injectable form of phenylephrine, can be administered without diluting, thus reducing the risk of medication errors waste caused due to overdrawing medication, Eton Pharmaceuticals said in an Oct. 22 press release.

Phenylephrine, which is a highly concentrated medication primarily used for its drying effect to increase blood pressure, is required to be manually diluted before a patient can have it. It could also be purchased from 503B compounding pharmacies, but because compounded drugs are not subjected to FDA review, they are often associated with higher risks of medication error, the company said.

Before the Deer Park, Ill.-based company received the regulator's approval, phenylephrine was the only approved medication available for lowering the anesthesia-induced low blood pressure.

Eton Pharmaceuticals CEO Sean Brynjelsen said the company plans to make Biorphen available to hospitals across the U.S. before 2019 end.